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Abstract
Summary In agreement with the results of animal studies,
the plasma osteocalcin level is positively associated with
improved glucose tolerance and insulin secretion and
sensitivity. In addition, the plasma osteocalcin level is
inversely associated with the development of diabetes;
however, the plasma adiponectin level may not be
involved in osteocalcin-mediated energy metabolism in
humans.
Introduction Recent animal studies have suggested cross-
talk between bone and energy metabolism through osteo-
calcin. The aims of this study were to determine whether or
not osteocalcin is associated with the improved glucose
tolerance and insulin secretion and sensitivity, and whether
or not the association is dependent on the plasma
adiponectin level in humans.
Methods Four hundred twenty-five subjects, 19–82 years of
age (mean age, 53 years), were enrolled. An oral glucose
tolerance test (OGTT) and OGTT-based methods that were
validated against the euglycemic clamp were determined.
Total osteocalcin, leptin, and total adiponectin levels were
measured.
Results The plasma levels of total osteocalcin were
significantly different between the normal glucose toler-
ance, pre-diabetes, and diabetes groups. The glucose
levels and homeostasis model assessment insulin resis-
tance values varied inversely with the osteocalcin tertiles,
and OGTT-based insulin secretion (HOMA-B%, disposi-
tion index) and insulin sensitivity indices (Stumvoll’s
and OGIS indices) were increased with the tertiles.
Although the plasma adiponectin level was positively
correlated with the osteocalcin level, no changes in the
association were noted between the plasma osteocalcin
level and the glucose tolerance or insulin secretion and
sensitivity indices after adjustment for the plasma
adiponectin level. Based on multiple logistic regression
analysis, the plasma osteocalcin level was inversely
associated with the development of type 2 diabetes
mellitus independent of age, gender, body mass index,
and fasting plasma glucose and plasma adiponectin
levels.
Conclusions Circulating osteocalcin level is associated
with improved glucose tolerance and insulin secretion and
sensitivity independent of the plasma adiponectin level in
humans.
Keywords Adiponectin.Insulin resistance.Insulin
secretion.Osteocalcin
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Recently,Lee etal.[1] have described a novel function of the
skeleton on energy metabolism. Specially, they demonstrated
that the osteoblast-specific protein, osteocalcin, is involved
in glucose metabolism by increasing insulin secretion and
cell proliferation in pancreatic β-cells and improving insulin
sensitivity by upregulating the expression of an insulin-
sensitizing adipokine (the adiponectin gene) in adipocytes.
Subsequent human studies, including our own work, have
confirmed the previous report [2–10]. Collectively, these
human studies have shown that the serum osteocalcin
concentration is negatively associated with the plasma glucose
level and body fat mass [3, 5–7] and positively associated
with insulin secretion [4, 8], lower insulin resistance [5–9],
and serum adiponectin concentration [3, 9]. In addition,
Kanazawa et al. [3] showed that the serum osteocalcin level is
negatively associated with the brachial-ankle pulse wave
velocity and carotid intima-media thickness and suggested
that osteocalcin might, thus, be linked to atherosclerosis.
To date, homeostasis model assessment (HOMA) values
have mainly been used to assess β-cell function and insulin
sensitivity and the involvement of osteocalcin on glucose
metabolism. However, the HOMA β-cell function index
(HOMA-B%) is proportional to the fasting insulin level and is
expected to be inversely related to insulin sensitivity in subjects
with normal glucose tolerance (NGT), and thus, adjustment for
insulin sensitivity is necessary [11]. Also, the agreement
between homeostasis model assessment insulin resistance
(HOMA-IR), an indicator of insulin resistance, and clamp-
measured insulin sensitivity is controversial, ranging from very
good to nonexistent [12]. Therefore, it is necessary to
determine the association between osteocalcin and insulin
secretion and insulin sensitivity with more valid methods. In
addition, it remains uncertain whether or not the insulin-
sensitizing and glucose-lowering effects of osteocalcin are truly
mediated by upregulation of the adiponectin gene in humans.
Therefore, we performed a study to determine whether or not
osteocalcin is positively correlated with insulin secretion and
insulin sensitivity using oral glucose tolerance test (OGTT)-
based methods that have been validated against the clamp. In
addition, we determined whether or not osteocalcin is inversely
associated with the development of type 2 diabetes mellitus
(T2DM) after adjusting for other diabetes risk factors and the
plasma adiponectin level in humans.
Methods
Subjects
We recruited study subjects from among those who
attended the Kyung Hee University Hospital at Gangdong
between December 2006 and July 2009 for the diagnosis,
evaluation, or treatment of diabetes. During this period,
1,785 subjects (942 males and 843 females) underwent a
75-g OGTT, and after acquiring informed consent, plasma
samples were obtained and stored at −70 C for future
studies involving cardiovascular disorders and diabetes.
The exclusion criteria applied were as follows: (1) history
of metabolic bone diseases, such as hyperparathyroidism;
(2) uncontrolled liver or thyroid diseases; (3) acute ill-
nesses, such as infection, surgery, and hospital admission
for a medical condition other than diabetes; (4) recent
history of a fracture (<6 months); and (5) medications
known to affect bone or glucose metabolism, such as
glucocorticoids or bisphosphonates.
In this study, diabetes mellitus was defined by the
presence of one of the following: (1) fasting glucose levels
at ≥126 mg/dl (≥7.0 mmol/l) or (2) 2-h post-load glucose
levels at ≥200 mg/dl (≥11.1 mmol/l). To eliminate the
effects of drugs on insulin secretion and sensitivity driven
by OGTT, we limited our study subjects to those who had
never been treated with oral glucose-lowering agents to
eliminate the effects on glucose tolerance, and insulin
secretion and sensitivity measured by OGTT. Finally, 425
subjects, 19–82 years of age (mean age, 53.0±12.0 years),
were enrolled in this study. According to the OGTT results,
subjects were diagnosed as follows: NGT (n=23); pre-
diabetes (n=150), which included subjects with impaired
fasting glucose (IFG), impaired glucose tolerance (IGT),
and both IFG and IGT; and diabetes (n=252). The study
was approved by the Ethics Committee and the Institutional
Review Board of Kyung Hee University Hospital and
complied with the Declaration of Helsinki.
Biochemical measurements
After an overnight fast (8~12 h), a 75-g OGTT was begun
between 0800 and 0900 hours according to standardized
clinical procedures. In brief, after a cannula was inserted in
an antecubital vein for blood sampling, basal blood samples
were drawn (0 min), then 75 g of glucose (Diasol®,
dissolved in 300 ml of water) was consumed within
5 min. Plasma glucose and insulin levels were then
determined 30, 60, 90, and 120 min after the glucose had
been administered. In addition, the plasma C-peptide levels
were measured at time 0 and 30 min.
To estimate insulin sensitivity, HOMA was used based
on fasting plasma glucose (FPG) and fasting plasma
insulin (FPI) concentrations. Insulin resistance was
estimated using HOMA-IR, which was defined as
follows: (FPI (μU/mL)×FPG (mmol/L))/22.5. In addi-
tion, we estimated insulin sensitivity in the subjects
using the three most extensively validated OGTT insulin
sensitivity indices against the euglycemic clamp tech-
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[13], MCRest [14], and OGIS [15]). To estimate β-cell
function, HOMA-B% was calculated as follows: (20×
FPI)/(FPG−3.5). The insulinogenic index was defined as
the ratio of insulin change to plasma glucose change
30 min after a 75-g oral glucose load (Δ insulin, 0–
30 min/Δ plasma glucose, 0–30 min) and was used to
estimate early phase insulin secretion. In addition, the area
under the curve (AUC) of glucose or insulin levels during
the OGTT was calculated by the trapezoidal rule, and the
ratio of the total AUC insulin to the total AUC glucose
(total AUC insulin/glucose) was used to measure the
summation of the total insulin secretory capacity [16]. The
disposition index was defined as the product of the
insulinogenic index and Matsuda’si n d e xa n dw a su s e d
for estimating the insulin secretory capacity adjusted for
insulin resistance.
The plasma glucose levels were determined using the
hexokinase method in an autoanalyzer (Hitachi, Tokyo,
Japan), which had a CV of 1.7%. The plasma insulin
(Biosource, Nivelles, Belgium) and C-peptide levels
(Immunotech, Czech Republic) were determined using
immunoradiometric assays with intra- and inter-assay
CVs of 1.6–2.2% and 6.1–6.5% and 2.3–3.0% and 3.5–
5.1%, respectively. The plasma total osteocalcin was
measured with an IRMA method using an Osteo-RIACT
kit from Cis Bio International (Saclay, France), which
had intra- and inter-assay CVs of 1.2–2.8% and 3.6–
5.2%, respectively. Total plasma adiponectin and leptin
levels were measured by ELISA kits (R&D Systems,
Minneapolis, MN, USA), as recommended by the
manufacturer.
Statistical methods
All data are presented as the means±SDs or proportions,
except for skewed variables, which were presented as the
median (interquartile range, 25–75%). Because the dis-
tributions of fasting and 2-h plasma insulin levels, AUC
insulin, AUC insulin/glucose, HbA1c level, HOMA
values, insulinogenic index, disposition index, adiponec-
tin level, and leptin level were skewed as assessed by the
Kolmogorov–Smirnov test, the natural logarithmic trans-
formation was applied in the statistical analysis. In the
interests of simplicity, nontransformed median values are
presented in the tables and text. One-way ANOVA,
followed by Turkey’s post hoc test, was used to compare
the means between the tertiles of osteocalcin levels.
Pearson correlation coefficients were calculated to eval-
uate the associations between osteocalcin and age, body
mass index (BMI), and metabolic parameters (glucose,
insulin, and insulin secretory and insulin sensitivity
indices). Multiple linear regression analysis was used to
determine the associations between plasma osteocalcin
and glucose tolerance, and insulin secretory or sensitivity
indices after adjusting for age, gender, BMI, and other
adipokines, including adiponectin and leptin levels. To
identify whether or not plasma total osteocalcin was
independently associated with the development of
T2DM, we performed a multivariate logistic regression
analysis with backward variable selection. Analysis was
performed using SPSS (version 13.0; SPSS, Inc. Chicago, IL,
USA), and p values of <0.05 were considered significant.
Results
We divided the study subjects according to glucose
tolerance status, and compared the plasma total osteo-
calcin levels. The plasma osteocalcin levels were signif-
icantly different between the groups (p<0.001); however,
no difference was noted in the osteocalcin levels between
the NGT (18.4±9.0 ng/ml) and pre-diabetes groups (19.1±
8.9 ng/ml). After the development of diabetes (15.3±
6.8 ng/ml), the plasma osteocalcin levels were decreased
compared with the pre-diabetes group (Fig. 1). Next, we
divided the subjects into tertiles (lower, middle, and
upper) by plasma osteocalcin levels; the glucose and
HbA1c levels varied inversely with the osteocalcin
tertiles, and the insulin secretory capacity, including the
AUC insulin/glucose, HOMA-B%, insulinogenic index,
and disposition index and insulin sensitivity index (Mat-
suda’s, Stumvoll’s, and OGIS indices), increased with the
osteocalcin tertiles. In addition, the plasma adiponectin
levels were increased with the osteocalcin tertiles; how-
ever, no difference was noted in the plasma leptin levels
with the osteocalcin tertiles (Table 1). To determine
whether or not plasma osteocalcin level is independently
associated with improved glucose tolerance and insulin
sensitivity and secretory capacity, multiple linear regres-
sion analyses were performed. The plasma osteocalcin
level was inversely associated with FPG and AUC glucose
levels and positively associated with the disposition index
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Fig. 1 Osteocalcin levels (means±SDs) by glucose tolerance status.
NGT normal glucose tolerance, Pre-DM pre-diabetes, DM diabetes. To
convert osteocalcin levels to nanomoles per liter, multiply by 0.171
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gender, BMI, and other adipokines including adiponectin
and leptin levels (Table 2). To investigate the independent
association between the osteocalcin level and diabetes, a
multiple logistic regression analysis was performed. The
analysis included age, gender, BMI, fasting plasma
glucose level, and plasma adiponectin, leptin, and osteo-
calcin levels. Our results indicated that age and the fasting
plasma glucose level appeared to be independently
associated with the development of diabetes; the plasma
osteocalcin level was inversely associated with the
development of diabetes (OR, 0.955; 95% CI, 0.919–
0.994, p=0.023; Table 3).
Discussion
In the present study, the plasma levels of osteocalcin were
inversely correlated with fasting and 2-h post-load plasma
glucose levels and AUC glucose during an OGTT. In
addition, the osteocalcin level was positively associated
with the parameters which were estimated by the OGTT,
reflecting β-cell function and insulin sensitivity. Until now,
the associations between osteocalcin and insulin secretion
and sensitivity were primarily measured by HOMA values;
however, the model predicts the fasting steady-state glucose
and insulin concentrations for a wide range of possible
combinations of insulin resistance and β-cell function, and
it is difficult to determine the true dynamic function of β-
cell insulin secretion. In addition, in subjects with severely
impaired β-cell function, HOMA-IR did not represent
appropriate insulin resistance status [17], and therefore the
agreement between HOMA-IR and clamp-measured insulin
sensitivity remains controversial [12]. The current study
was unique and powered because we determined the
association between plasma osteocalcin levels and insulin
sensitivity with OGTT-driven dynamic methods that have
been extensively validated against euglycemic clamp
methods, and determined the β-cell function with diverse
parameters, including the HOMA-B%, insulinogenic index,
AUC insulin/glucose, and disposition index.
According to the original observation by Lee et al. [1],
osteocalcin regulates insulin sensitivity, at least in part,
through adiponectin gene expression. In the current study,
the plasma adiponectin levels were significantly different
across the osteocalcin tertiles (p<0.001) and were positively
correlated with the indices representing insulin sensitivity,
including Matsuda’s, Stumvoll’s, and OGIS indices (data not
shown, all p<0.01). In multiple linear regression analyses,
however, the plasma osteocalcin levels were still signifi-
Table 1 Insulin secretion and sensitivity by osteocalcin tertiles
Variable Osteocalcin lower tertile
(n=141)
Osteocalcin middle tertile
(n=143)
Osteocalcin upper tertile
(n=141)
p
Osteocalcin (ng/ml, range) 9.1±3.2 (1.1–13.0) 15.7±1.7 (13.1–18.9) 25.3±6.7 (19.0–70.7) <0.001
Age (year) 53.2±13.1 52.0±11.9 54.0±10.9 NS
Gender (male/female) 74/67 89/54 60/81 NS
BMI (kg/m
2) 25.3±3.5 25.5±3.8 25.5±3.8 NS
Glucose (0′) (mg/dl) 155.0±66.7 126.1±30.6 118.9±28.8 <0.001
Insulin (0′)( μIU/ml) 10.1 (7.2–14.5) 10.7 (8.4–14.2) 9.9 (7.4–12.9) 0.046
HbA1c (%) 7.7±2.4 6.6±1.3 6.4±1.3 <0.001
AUC glucose (0–120′) 28.2±10.7 24.1±6.8 22.8±6.9 <0.001
AUC insulin (0–120′) 323.2 (204.9–573.6) 438.2 (280.6–693.0) 400.5 (263.7–662.9) <0.001
AUC insulin/glucose (0–120′) 13.5 (7.0–26.0) 18.4 (11.6–34.9) 19.7 (11.4–31.9) <0.001
HOMA-IR 3.44 (2.45–5.21) 3.47 (2.52–4.26) 2.82 (2.05–3.87) 0.002
HOMA-B% 58.6 (32.0–91.7) 74.2 (49.0–104.8) 75.5 (54.6–97.5) <0.001
Insulinogenic index 0.18 (0.08–0.44) 0.29 (0.15–0.58) 0.32 (0.14–0.57) <0.001
Matsuda’s index 4.12±2.01 3.85±1.81 4.53±2.22 0.018
Disposition index 0.63 (0.27–1.53) 1.04 (0.50–1.86) 1.09 (0.60–2.30) <0.001
Stumvoll’s index 6.40±2.24 6.57±2.72 7.10±2.22 0.040
OGIS index 324.0±76.9 350.3±57.3 369.7±57.4 <0.001
Plasma adiponectin level (μg/ml) 2.20 (1.44–2.93) 1.80 (1.35–3.20) 2.43 (1.68–3.83) <0.001
Plasma leptin level (μg/l) 5.44 (2.28–13.89) 4.82 (2.66–8.37) 4.57 (1.72–14.80) NS
Data are presented as the means±SDs or median (interquartile range, 25–75%), except as otherwise indicated. To convert glucose levels to
milimoles per liter, multiply by 0.0555. To convert insulin levels to picomoles per liter, multiply by 6.945
BMI body mass index, AUC area under the curve, HOMA homeostasis model assessment, ND not determined, NS not significant
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insulin secretion and sensitivity indices even after con-
trolling for the adiponectin levels. Therefore, adiponectin
did not mediate the association between the osteocalcin
level and glucose tolerance and insulin secretion and
sensitivity in humans. In addition, we investigated
whether or not the plasma osteocalcin level is inversely
associated with the development of T2DM. The results
indicated that the plasma osteocalcin level is inversely
associated with the development of T2DM independent of
well-established risk factors for diabetes, such as age,
gender, BMI, and baseline fasting plasma glucose level
and circulating adipokines including plasma adiponectin
and leptin levels. These results suggest that osteocalcin-
mediated increased insulin sensitivity may not involve
adiponectin gene upregulation in humans but may involve
other mechanisms. This is the first report to demonstrate
an independent association, especially independent of
plasma adiponectin levels, between plasma osteocalcin
levels and improved glucose tolerance and insulin secretion
and sensitivity. In contrast with our results, Shea et al. [9]
reported that the strength of the association between total
osteocalcin and carboxylated osteocalcin with HOMA-IR is
somewhat attenuated after adiponectin is accounted for;
therefore, they concluded that the association between total
osteocalcin and carboxylated osteocalcin with HOMA-IR
may depend partially on adiponectin. Although we could not
explain the discrepancy between the studies, the different
levels of insulin resistance between the study subjects
and different measurements assessing insulin sensitivity
may be casual.
In the current study, no difference in the osteocalcin
level was noted between the NGT and pre-diabetes groups,
and the level of the pre-diabetes group was somewhat
higher compared with the NGT group, although it did not
reach statistical significance. Therefore, it is not until
diabetes develops that plasma osteocalcin levels are
decreased. As a plausible explanation for this finding, it is
possible that osteoblasts may secrete more osteocalcin to
overcome a given amount of insulin resistance, and more
insulin is initially secreted in pancreatic β-cells (pre-
diabetes state). However, as insulin resistance becomes
more severe, the osteoblast fails to secrete sufficient
osteocalcin, insulin secretion is decreased, and diabetes
finally develops. In partial agreement with our speculation,
Winhofer et al. [10] reported that women with gestational
diabetes have higher osteocalcin levels compared with
women with NGT during pregnancy while no difference
was observed between the two groups 12 weeks postpar-
tum, and therefore, they hypothesized that osteocalcin can
enhance insulin secretion in insulin-resistant states.
This study had several limitations. First, this study was
based on a cross-sectional analysis, and thus, we do not
know whether or not our findings are merely correlations or
if osteocalcin has direct glucose-lowering effects in human
subjects, as in animal- and cell-based studies. Second, we
did not differentiate plasma osteocalcin with respect to the
gamma-carboxylation status, and only measured the total
form of osteocalcin, instead of directly measuring carbox-
ylated and uncarboxylated osteocalcin. Therefore, we do
not know the differential mechanism of both types of
osteocalcin to regulate insulin secretion and insulin sensi-
tivity. Third, it is known that the levels of bone turnover
markers, including plasma osteocalcin, are different accord-
ing to age, gender, and race or ethnicity [18]. In this study,
although we adjusted for age and gender, we could not
entirely exclude the effects of age and gender on the
associations between plasma osteocalcin levels and glucose
Table 2 Multiple linear regression analysis for glucose tolerance and insulin secretion and sensitivity indices
Variable FPG AUC glucose (0–120′) Disposition index Matsuda’s index Stumvoll’s index OGIS index
Age −0.048 0.030 −0.170*** −0.110* −0.104* −0.066
BMI −0.029 0.016 −0.077 −0.325*** −0.526*** −0.142**
Adiponectin −0.092 −0.131** 0.134** 0.059 0.048 0.141**
Leptin −0.081 −0.098 0.127* −0.182*** −0.047 0.029
Osteocalcin −0.269*** −0.255*** 0.142** 0.064 0.141** 0.240***
Standard β values from multiple linear regression analysis
BMI body mass index
*p<0.05; **p<0.01; ***p<0.001
Table 3 Multiple logistic regression analysis for diabetes
Variable OR per 1-SD increase in
variable (95% CI)
p
Age 1.577 (1.152–2.160) 0.005
Fasting plasma glucose 471.399 (120.817–1,839.284) <0.001
Total osteocalcin 0.726 (0.533–0.988) 0.042
Age, gender, body mass index, fasting plasma glucose, plasma
adiponectin, leptin, and osteocalcin levels were included as dependent
variables
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resorption at low pH is necessary to decarboxylate
osteocalcin, and thus, osteoclasts determine the carboxyla-
tion status and function of osteocalcin in mice [19] and
possibly in humans [20]. Therefore, the additional mea-
surement of bone resorption markers may further clarify the
potential association between bone resorption, osteocalcin,
and glucose homeostasis in humans.
In conclusion, an elevated plasma osteocalcin level was
associated with improved glucose tolerance and may be
associated with increased β-cell function and insulin
sensitivity. However, it appears that the glucose-lowering
and insulin-sensitizing effect of osteocalcin is not mediated
by an increment in the plasma adiponectin level in humans.
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